Reata Pharmaceuticals, Inc. (NASDAQ:RETA) CFO Manmeet Singh Soni Sells 3,587 Shares

Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) CFO Manmeet Singh Soni sold 3,587 shares of the company’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $87.97, for a total value of $315,548.39. Following the sale, the chief financial officer now owns 88,926 shares in the company, valued at approximately $7,822,820.22. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Reata Pharmaceuticals Trading Down 2.6 %

Shares of RETA stock opened at $88.51 on Tuesday. The stock has a 50 day simple moving average of $44.03 and a 200 day simple moving average of $35.61. Reata Pharmaceuticals, Inc. has a 1 year low of $18.47 and a 1 year high of $95.00. The stock has a market cap of $3.25 billion, a P/E ratio of -10.31 and a beta of 1.27.

Institutional Trading of Reata Pharmaceuticals

Large investors have recently modified their holdings of the stock. AXA S.A. acquired a new stake in Reata Pharmaceuticals during the third quarter worth about $317,000. BNP Paribas Arbitrage SA lifted its stake in Reata Pharmaceuticals by 43.7% during the second quarter. BNP Paribas Arbitrage SA now owns 81,972 shares of the company’s stock worth $2,491,000 after purchasing an additional 24,938 shares during the last quarter. Endurant Capital Management LP acquired a new stake in shares of Reata Pharmaceuticals in the 3rd quarter valued at $612,000. Woodstock Corp increased its stake in shares of Reata Pharmaceuticals by 9.0% in the 3rd quarter. Woodstock Corp now owns 14,685 shares of the company’s stock valued at $369,000 after purchasing an additional 1,212 shares during the last quarter. Finally, Sofinnova Investments Inc. raised its holdings in shares of Reata Pharmaceuticals by 4.4% during the 3rd quarter. Sofinnova Investments Inc. now owns 818,376 shares of the company’s stock worth $20,566,000 after buying an additional 34,525 shares in the last quarter. 76.13% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on RETA. Robert W. Baird boosted their price objective on shares of Reata Pharmaceuticals from $40.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, March 1st. Cantor Fitzgerald boosted their target price on Reata Pharmaceuticals from $61.00 to $121.00 and gave the stock an “overweight” rating in a report on Wednesday, March 1st. Citigroup raised their price target on Reata Pharmaceuticals from $53.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, March 1st. SVB Securities increased their price objective on shares of Reata Pharmaceuticals from $35.00 to $75.00 in a research report on Wednesday, March 1st. Finally, Barclays increased their price target on shares of Reata Pharmaceuticals from $50.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, March 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $95.00.

Reata Pharmaceuticals Company Profile

(Get Rating)

Reata Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.